Guidelines on Testicular Cancer: 2015 Update

European Urology

Volumn 68, Issue 6, 2015, Pages 1054-1068

  Albers, Peter ^a   Albrecht, Walter ^b   Algaba, Ferran ^c   Bokemeyer, Carsten ^d   Cohn Cedermark, Gabriella ^e   Fizazi, Karim ^f   Horwich, Alan ^g   Laguna, Maria Pilar ^h   Nicolai, Nicola ⁱ   Oldenburg, Jan ^b  

^a UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^b Department of Urology ^*  (Norway)

^c FUNDACIÓ PUIGVERT   (Spain)

^d UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^e KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^f UNIVERSITÉ PARIS SACLAY   (France)

^g INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^h UNIVERSITY OF AMSTERDAM   (Netherlands)

ⁱ NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Chemotherapy; EAU guidelines; Follow up; Germ cell tumour; Metastatic disease; Relapse; Retroperitoneal lymph node dissection; Risk adapted treatment; Testis cancer

Indexed keywords

BLEOMYCIN; CARBOPLATIN; CISPLATIN; ETOPOSIDE;

ADJUVANT THERAPY; ARTICLE; CANCER ADJUVANT THERAPY; CANCER DIAGNOSIS; CANCER GROWTH; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; FOLLOW UP; HUMAN; LYMPH NODE DISSECTION; MALE; MEDICAL ONCOLOGIST; METASTASIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; RADIATION ONCOLOGIST; RELAPSE; SEMINOMA; TESTICULAR INTRAEPITHELIAL NEOPLASIA; TESTIS CANCER; TESTIS NONSEMINOMA CANCER; TESTIS TUMOR; UROLOGIST; DECISION TREE; TESTICULAR NEOPLASMS;

DECISION TREES; HUMANS; MALE; NEOPLASM STAGING; TESTICULAR NEOPLASMS;

EID: 84983109598     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2015.07.044     Document Type: Article

References (103)

1. R. Hoffmann, I. Plug, M. McKee, and et al. Innovations in health care and mortality trends from five cancers in seven European countries between 1970 and 2005 Int J Public Health 59 2014 341 350
2. A. Jones, J.N. Fergus, J. Chapman, and L. Houghton Is surveillance for stage 1 germ cell tumours of the testis appropriate outside a specialist centre? BJU Int 84 1999 79 84
3. L. Collette, R.J. Sylvester, S.P. Stenning, and et al. Impact of the treating institution on survival of patients with "poor-prognosis" metastatic nonseminoma J Natl Cancer Inst 91 1999 839 846
4. U. Capitanio, C. Jeldres, P. Perrotte, and et al. Population-based study of perioperative mortality after retroperitoneal lymphadenectomy for nonseminomatous testicular germ cell tumors Urology 74 2009 373 377
5. A. Flechon, E. Tavernier, H. Boyle, P. Meeus, M. Rivoire, and J.P. Droz Long-term oncological outcome after post-chemotherapy retroperitoneal lymph node dissection in men with metastatic nonseminomatous germ cell tumour BJU Int 106 2010 779 785
6. F. Zengerling, M. Hartmann, A. Heidenreich, and et al. German second-opinion network for testicular cancer: sealing the leaky pipe between evidence and clinical practice Oncol Rep 31 2014 2477 2481
7. P. Albers, W. Albrecht, F. Algaba, and et al. EAU Guidelines on testicular cancer: 2011 update Eur Urol 60 2011 304 319
8. J. Howick Levels of evidence 2009 Centre for Evidence-based Medicine Oxford, UK http://www.cebm.net/oxford-centre-evidence-based-medicine-levels-evidence-march-2009/
9. L.H. Sobin, M.K. Gospodarowicz, and C. Wittekind TNM classification of malignant tumors ed. 7 2009 Wiley-Blackwell Oxford, UK 249 254
10. G.M. Mead, and S.P. Stenning The International Germ Cell Consensus Classification: a new prognostic factor-based staging classification for metastatic germ cell tumours Clin Oncol 9 1997 207 209
11. K.P. Dieckmann, and V. Loy Prevalence of contralateral testicular intraepithelial neoplasia in patients with testicular germ cell neoplasms J Clin Oncol 14 1996 3126 3132
12. H. von der Maase, M. Rorth, S. Walbom-Jorgensen, and et al. Carcinoma in situ of contralateral testis in patients with testicular germ cell cancer: study of 27 cases in 500 patients BMJ 293 1986 1398 1401
13. S.J. Harland, P.A. Cook, S.D. Fossa, and et al. Intratubular germ cell neoplasia of the contralateral testis in testicular cancer: defining a high risk group J Urol 160 1998 1353 1357
14. K.P. Dieckmann, M. Kulejewski, U. Pichlmeier, and V. Loy Diagnosis of contralateral testicular intraepithelial neoplasia (TIN) in patients with testicular germ cell cancer: systematic two-site biopsies are more sensitive than a single random biopsy Eur Urol 51 2007 175 185
15. J. Classen, K. Dieckmann, M. Bamberg, and et al. Radiotherapy with 16 Gy may fail to eradicate testicular intraepithelial neoplasia: preliminary communication of a dose-reduction trial of the German Testicular Cancer Study Group Br J Cancer 88 2003 828 831
16. P.M. Petersen, A. Giwercman, G. Daugaard, and et al. Effect of graded testicular doses of radiotherapy in patients treated for carcinoma-in-situ in the testis J Clin Oncol 20 2002 1537 1543
17. A. Heidenreich, W. Holtl, W. Albrecht, J. Pont, and U.H. Engelmann Testis-preserving surgery in bilateral testicular germ cell tumours Br J Urol 79 1997 253 257
18. J. Aparicio, J.R. Germa, X. Garcia del Muro, and et al. Risk-adapted management for patients with clinical stage I seminoma: the Second Spanish Germ Cell Cancer Cooperative Group study J Clin Oncol 23 2005 8717 8723
19. P. Albers, R. Siener, S. Kliesch, and et al. Risk factors for relapse in clinical stage I nonseminomatous testicular germ cell tumors: results of the German Testicular Cancer Study Group trial J Clin Oncol 21 2003 1505 1512
20. J. Aparicio, P. Maroto, X. Garcia del Muro, and et al. Prognostic factors for relapse in stage I seminoma: a new nomogram derived from three consecutive, risk-adapted studies from the Spanish Germ Cell Cancer Group (SGCCG) Ann Oncol 25 2014 2173 2178
21. T. Tandstad, R. Smaaland, A. Solberg, and et al. Management of seminomatous testicular cancer: a binational prospective population-based study from the Swedish Norwegian Testicular Cancer Study Group J Clin Oncol 29 2011 719 725
22. J. Aparicio, X. Garcia del Muro, P. Maroto, and et al. Multicenter study evaluating a dual policy of postorchiectomy surveillance and selective adjuvant single-agent carboplatin for patients with clinical stage I seminoma Ann Oncol 14 2003 867 872
23. R.T. Oliver, G.M. Mead, G.J. Rustin, and et al. Randomized trial of carboplatin versus radiotherapy for stage I seminoma: mature results on relapse and contralateral testis cancer rates in MRC TE19/EORTC 30982 study (ISRCTN27163214) J Clin Oncol 29 2011 957 962
24. R.T. Oliver, M.D. Mason, G.M. Mead, and et al. Radiotherapy versus single-dose carboplatin in adjuvant treatment of stage I seminoma: a randomised trial Lancet 366 2005 293 300
25. G.M. Mead, S.D. Fossa, R.T. Oliver, and et al. Randomized trials in 2466 patients with stage I seminoma: patterns of relapse and follow-up J Natl Cancer Inst 103 2011 241 249
26. P. Schoffski, N. Höhn, R. Kowalski, and et al. Health-related quality of life (QoL) in patients with seminoma stage I treated with either adjuvant radiotherapy (RT) or two cycles of carboplatinum chemotherapy (CT): results of a randomized phase III trial of the German Interdisciplinary Working Party on Testicular Cancer J Clin Oncol 25 18 Suppl 2007 5050
27. S.D. Fossa, A. Horwich, J.M. Russell, and et al. Optimal planning target volume for stage I testicular seminoma: a Medical Research Council randomized trial J Clin Oncol 17 1999 1146
28. W.G.F.S. Jones, G.M. Mead, and et al. A randomized trial of two radiotherapy schedules in the adjuvant treatment of stage I seminoma (MRC TE 18) Eur J Cancer 37 2001 572
29. D. Melchior, P. Hammer, R. Fimmers, H. Schuller, and P. Albers Long term results and morbidity of paraaortic compared with paraaortic and iliac adjuvant radiation in clinical stage I seminoma Anticancer Res 21 2001 2989 2993
30. A.W. van den Belt-Dusebout, R. de Wit, J.A. Gietema, and et al. Treatment-specific risks of second malignancies and cardiovascular disease in 5-year survivors of testicular cancer J Clin Oncol 25 2007 4370 4378
31. A. Horwich, S.D. Fossa, R. Huddart, and et al. Second cancer risk and mortality in men treated with radiotherapy for stage I seminoma Br J Cancer 110 2014 256 263
32. J. Aparicio, P. Maroto, X. Garcia del Muro, and et al. Risk-adapted treatment in clinical stage I testicular seminoma: the third Spanish Germ Cell Cancer Group study J Clin Oncol 29 2011 4677 4681
33. L.S. Freedman, M.C. Parkinson, W.G. Jones, and et al. Histopathology in the prediction of relapse of patients with stage I testicular teratoma treated by orchidectomy alone Lancet 2 1987 294 298
34. G. Read, S.P. Stenning, M.H. Cullen, and et al. Medical Research Council prospective study of surveillance for stage I testicular teratoma J Clin Oncol 10 1992 1762 1768
35. G. Daugaard, I. Skoneczna, N. Aass, and et al. A randomized phase III study comparing standard dose BEP with sequential high-dose cisplatin, etoposide, and ifosfamide (VIP) plus stem-cell support in males with poor-prognosis germ-cell cancer. An intergroup study of EORTC, GTCSG, and Grupo Germinal (EORTC 30974) Ann Oncol 22 2011 1054 1061
36. C. Kollmannsberger, T. Tandstad, P.L. Bedard, and et al. Patterns of relapse in patients with clinical stage I testicular cancer managed with active surveillance J Clin Oncol 33 2015 51 57
37. C. Kollmannsberger, C. Moore, K.N. Chi, and et al. Non-risk-adapted surveillance for patients with stage I nonseminomatous testicular germ-cell tumors: diminishing treatment-related morbidity while maintaining efficacy Ann Oncol 21 2010 1296 1301
38. C.R. Nichols, B. Roth, P. Albers, and et al. Active surveillance is the preferred approach to clinical stage I testicular cancer J Clin Oncol 31 2013 3490 3493
39. M.H. Cullen, S.P. Stenning, M.C. Parkinson, and et al. Short-course adjuvant chemotherapy in high-risk stage I nonseminomatous germ cell tumors of the testis: a Medical Research Council report J Clin Oncol 14 1996 1106 1113
40. J. Pont, W. Albrecht, G. Postner, F. Sellner, K. Angel, and W. Holtl Adjuvant chemotherapy for high-risk clinical stage I nonseminomatous testicular germ cell cancer: long-term results of a prospective trial J Clin Oncol 14 1996 441 448
41. D. Bohlen, F.C. Burkhard, R. Mills, R.W. Sonntag, and U.E. Studer Fertility and sexual function following orchiectomy and 2 cycles of chemotherapy for stage I high risk nonseminomatous germ cell cancer J Urol 165 2001 441 444
42. R.A. Huddart, A. Norman, M. Shahidi, and et al. Cardiovascular disease as a long-term complication of treatment for testicular cancer J Clin Oncol 21 2003 1513 1523
43. P. Albers, R. Siener, S. Krege, and et al. Randomized phase III trial comparing retroperitoneal lymph node dissection with one course of bleomycin and etoposide plus cisplatin chemotherapy in the adjuvant treatment of clinical stage I nonseminomatous testicular germ cell tumors: AUO trial AH 01/94 by the German Testicular Cancer Study Group J Clin Oncol 26 2008 2966 2972
44. T. Tandstad, O. Dahl, G. Cohn-Cedermark, and et al. Risk-adapted treatment in clinical stage I nonseminomatous germ cell testicular cancer: the SWENOTECA management program J Clin Oncol 27 2009 2122 2128
45. T. Tandstad, O. Stahl, U. Hakansson, and et al. One course of adjuvant BEP in clinical stage I nonseminoma mature and expanded results from the SWENOTECA group Ann Oncol 25 2014 2167 2172
46. P. Maroto, X. Garcia del Muro, J. Aparicio, and et al. Multicentre risk-adapted management for stage I non-seminomatous germ cell tumours Ann Oncol 16 2005 1915 1920
47. T. Tandstad, G. Cohn-Cedermark, O. Dahl, and et al. Long-term follow-up after risk-adapted treatment in clinical stage 1 (CS1) nonseminomatous germ-cell testicular cancer (NSGCT) implementing adjuvant CVB chemotherapy. A SWENOTECA study Ann Oncol 21 2010 1858 1863
48. A. Heidenreich, P. Albers, M. Hartmann, and et al. Complications of primary nerve sparing retroperitoneal lymph node dissection for clinical stage I nonseminomatous germ cell tumors of the testis: experience of the German Testicular Cancer Study Group J Urol 169 2003 1710 1714
49. M. Neyer, R. Peschel, T. Akkad, and et al. Long-term results of laparoscopic retroperitoneal lymph-node dissection for clinical stage I nonseminomatous germ-cell testicular cancer J Endourol 21 2007 180 183
50. A. Lorch, J. Beyer, C. Bascoul-Mollevi, and et al. Prognostic factors in patients with metastatic germ cell tumors who experienced treatment failure with cisplatin-based first-line chemotherapy J Clin Oncol 28 2010 4906 4911
51. J. Classen, H. Schmidberger, C. Meisner, and et al. Radiotherapy for stages IIA/B testicular seminoma: final report of a prospective multicenter clinical trial J Clin Oncol 21 2003 1101 1106
52. P.W. Chung, M.K. Gospodarowicz, T. Panzarella, and et al. Stage II testicular seminoma: patterns of recurrence and outcome of treatment Eur Urol 45 2004 754 759
53. A. Horwich, D.P. Dearnaley, A. Sohaib, K. Pennert, and R.A. Huddart Neoadjuvant carboplatin before radiotherapy in stage IIA and IIB seminoma Ann Oncol 24 2013 2104 2107
54. S. Krege, C. Boergermann, R. Baschek, and et al. Single agent carboplatin for CS IIA/B testicular seminoma. A phase II study of the German Testicular Cancer Study Group (GTCSG) Ann Oncol 17 2006 276 280
55. A.J. Stephenson, G.J. Bosl, R.J. Motzer, D.F. Bajorin, J.P. Stasi, and J. Sheinfeld Nonrandomized comparison of primary chemotherapy and retroperitoneal lymph node dissection for clinical stage IIA and IIB nonseminomatous germ cell testicular cancer J Clin Oncol 25 2007 5597 5602
56. L. Weissbach, R. Bussar-Maatz, H. Flechtner, U. Pichlmeier, M. Hartmann, and L. Keller RPLND or primary chemotherapy in clinical stage IIA/B nonseminomatous germ cell tumors? Results of a prospective multicenter trial including quality of life assessment Eur Urol 37 2000 582 594
57. A. Horwich, A. Norman, C. Fisher, W.F. Hendry, J. Nicholls, and D.P. Dearnaley Primary chemotherapy for stage II nonseminomatous germ cell tumors of the testis J Urol 151 1994 72 77
58. J.P. Donohue, J.A. Thornhill, R.S. Foster, R. Bihrle, R.G. Rowland, and L.H. Einhorn The role of retroperitoneal lymphadenectomy in clinical stage B testis cancer: the Indiana University experience (1965 to 1989) J Urol 153 1995 85 89
59. C. Bokemeyer, C. Kollmannsberger, S. Stenning, and et al. Metastatic seminoma treated with either single agent carboplatin or cisplatin-based combination chemotherapy: a pooled analysis of two randomised trials Br J Cancer 91 2004 683 687
60. K. Fizazi, R. Delva, A. Caty, and et al. A risk-adapted study of cisplatin and etoposide, with or without ifosfamide, in patients with metastatic seminoma: results of the GETUG S99 multicenter prospective study Eur Urol 65 2014 381 386
61. R. de Wit, J.T. Roberts, P.M. Wilkinson, and et al. Equivalence of three or four cycles of bleomycin, etoposide, and cisplatin chemotherapy and of a 3- or 5-day schedule in good-prognosis germ cell cancer: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group and the Medical Research Council J Clin Oncol 19 2001 1629 1640
62. R. de Wit, I. Skoneczna, G. Daugaard, and et al. Randomized phase III study comparing paclitaxel-bleomycin, etoposide, and cisplatin (BEP) to standard BEP in intermediate-prognosis germ-cell cancer: intergroup study EORTC 30983 J Clin Oncol 30 2012 792 799
63. R.J. Motzer, C.J. Nichols, K.A. Margolin, and et al. Phase III randomized trial of conventional-dose chemotherapy with or without high-dose chemotherapy and autologous hematopoietic stem-cell rescue as first-line treatment for patients with poor-prognosis metastatic germ cell tumors J Clin Oncol 25 2007 247 256
64. J.P. Droz, A. Kramar, P. Biron, and et al. Failure of high-dose cyclophosphamide and etoposide combined with double-dose cisplatin and bone marrow support in patients with high-volume metastatic nonseminomatous germ-cell tumours: mature results of a randomised trial Eur Urol 51 2007 739 748
65. K. Fizazi, L. Pagliaro, A. Laplanche, and et al. Personalised chemotherapy based on tumour marker decline in poor prognosis germ-cell tumours (GETUG 13): a phase 3, multicentre, randomised trial Lancet Oncol 15 2014 1442 1450
66. S.E. Olofsson, T. Tandstad, M. Jerkeman, and et al. Population-based study of treatment guided by tumor marker decline in patients with metastatic nonseminomatous germ cell tumor: a report from the Swedish-Norwegian Testicular Cancer Group J Clin Oncol 29 2011 2032 2039
67. C. Bokemeyer, C. Kollmannsberger, C. Meisner, and et al. First-line high-dose chemotherapy compared with standard-dose PEB/VIP chemotherapy in patients with advanced germ cell tumors: A multivariate and matched-pair analysis J Clin Oncol 17 1999 3450 3456
68. C. Thibault, K. Fizazi, D. Barrios, and et al. Compliance with guidelines and correlation with outcome in patients with advanced germ-cell tumours Eur J Cancer 50 2014 1284 1290
69. C. Massard, A. Plantade, M. Gross-Goupil, and et al. Poor prognosis nonseminomatous germ-cell tumours (NSGCTs): should chemotherapy doses be reduced at first cycle to prevent acute respiratory distress syndrome in patients with multiple lung metastases? Ann Oncol 21 2010 1585 1588
70. S. Gillessen, T. Powles, L. Lim, P. Wilson, and J. Shamash Low-dose induction chemotherapy with Baby-BOP in patients with metastatic germ-cell tumours does not compromise outcome: a single-centre experience Ann Oncol 21 2010 1589 1593
71. 18Fluoro-deoxy-D-glucose positron emission tomography is a reliable predictor for viable tumor in postchemotherapy seminoma: an update of the prospective multicentric SEMPET trial J Clin Oncol 22 2004 1034 1039
72. B.S. Carver, A.M. Serio, D. Bajorin, and et al. Improved clinical outcome in recent years for men with metastatic nonseminomatous germ cell tumors J Clin Oncol 25 2007 5603 5608
73. 18F]Fluorodeoxyglucose positron emission tomography in nonseminomatous germ cell tumors after chemotherapy: the German multicenter positron emission tomography study group J Clin Oncol 26 2008 5930 5935
74. C. Kollmannsberger, S. Daneshmand, A. So, and et al. Management of disseminated nonseminomatous germ cell tumors with risk-based chemotherapy followed by response-guided postchemotherapy surgery J Clin Oncol 28 2010 537 542
75. Y. Ehrlich, M.J. Brames, S.D. Beck, R.S. Foster, and L.H. Einhorn Long-term follow-up of Cisplatin combination chemotherapy in patients with disseminated nonseminomatous germ cell tumors: is a postchemotherapy retroperitoneal lymph node dissection needed after complete remission? J Clin Oncol 28 2010 531 536
76. E.W. Steyerberg, H.J. Keizer, and J.D. Habbema Prediction models for the histology of residual masses after chemotherapy for metastatic testicular cancer. ReHiT Study Group Int J Cancer 83 1999 856 859
77. B.S. Carver, B. Shayegan, A. Serio, R.J. Motzer, G.J. Bosl, and J. Sheinfeld Long-term clinical outcome after postchemotherapy retroperitoneal lymph node dissection in men with residual teratoma J Clin Oncol 25 2007 1033 1037
78. J. Oldenburg, G.C. Alfsen, H.H. Lien, N. Aass, H. Waehre, and S.D. Fossa Postchemotherapy retroperitoneal surgery remains necessary in patients with nonseminomatous testicular cancer and minimal residual tumor masses J Clin Oncol 21 2003 3310 3317
79. J. Baniel, R.S. Foster, R.G. Rowland, R. Bihrle, and J.P. Donohue Complications of post-chemotherapy retroperitoneal lymph node dissection J Urol 153 1995 976 980
80. K. Fizazi, J. Oldenburg, A. Dunant, and et al. Assessing prognosis and optimizing treatment in patients with postchemotherapy viable nonseminomatous germ-cell tumors (NSGCT): results of the sCR2 international study Ann Oncol 19 2008 259 264
81. A. Heidenreich, D. Pfister, R. Witthuhn, D. Thuer, and P. Albers Postchemotherapy retroperitoneal lymph node dissection in advanced testicular cancer: radical or modified template resection Eur Urol 55 2009 217 226
82. S.D. Beck, R.S. Foster, R. Bihrle, J.P. Donohue, and L.H. Einhorn Is full bilateral retroperitoneal lymph node dissection always necessary for postchemotherapy residual tumor? Cancer 110 2007 1235 1240
83. J.P. Calestroupat, R. Sanchez-Salas, X. Cathelineau, and et al. Postchemotherapy laparoscopic retroperitoneal lymph node dissection in nonseminomatous germ-cell tumor J Endourol 23 2009 645 650
84. J. Busch, A. Magheli, B. Erber, and et al. Laparoscopic and open postchemotherapy retroperitoneal lymph node dissection in patients with advanced testicular cancer - a single center analysis BMC Urol 12 2012 15
85. Y. Arai, Y. Kaiho, S. Yamada, and et al. Extraperitoneal laparoscopic retroperitoneal lymph node dissection after chemotherapy for nonseminomatous testicular germ-cell tumor: surgical and oncological outcomes Int Urol Nephrol 44 2012 1389 1395
86. B. Besse, D. Grunenwald, A. Flechon, and et al. Nonseminomatous germ cell tumors: assessing the need for postchemotherapy contralateral pulmonary resection in patients with ipsilateral complete necrosis J Thorac Cardiovasc Surg 137 2009 448 452
87. J. Schirren, S. Trainer, M. Eberlein, A. Lorch, J. Beyer, and S. Bolukbas The role of residual tumor resection in the management of nonseminomatous germ cell cancer of testicular origin Thorac Cardiovasc Surg 60 2012 405 412
88. Y. Ehrlich, D. Kedar, A. Zelikovski, M. Konichezky, and J. Baniel Vena caval reconstruction during postchemotherapy retroperitoneal lymph node dissection for metastatic germ cell tumor Urology 73 2009 442.e17-9
89. S.D. Beck, R.S. Foster, R. Bihrle, M.O. Koch, G.R. Wahle, and J.P. Donohue Aortic replacement during post-chemotherapy retroperitoneal lymph node dissection J Urol 165 2001 1517 1520
90. C. Winter, D. Pfister, J. Busch, and et al. Residual tumor size and IGCCCG risk classification predict additional vascular procedures in patients with germ cell tumors and residual tumor resection: a multicenter analysis of the German Testicular Cancer Study Group Eur Urol 61 2012 403 409
91. K. Oechsle, C. Kollmannsberger, F. Honecker, and et al. Long-term survival after treatment with gemcitabine and oxaliplatin with and without paclitaxel plus secondary surgery in patients with cisplatin-refractory and/or multiply relapsed germ cell tumors Eur Urol 60 2011 850 855
92. N. Nicolai, A. Necchi, L. Gianni, and et al. Long-term results of a combination of paclitaxel, cisplatin and gemcitabine for salvage therapy in male germ-cell tumours BJU Int 104 2009 340 346
93. K. Fizazi, G. Gravis, A. Flechon, and et al. Combining gemcitabine, cisplatin, and ifosfamide (GIP) is active in patients with relapsed metastatic germ-cell tumors (GCT): a prospective multicenter GETUG phase II trial Ann Oncol 25 2014 987 991
94. A. Lorch, C. Kollmannsberger, J.T. Hartmann, and et al. Single versus sequential high-dose chemotherapy in patients with relapsed or refractory germ cell tumors: a prospective randomized multicenter trial of the German Testicular Cancer Study Group J Clin Oncol 25 2007 2778 2784
95. K. Oechsle, A. Lorch, F. Honecker, and et al. Patterns of relapse after chemotherapy in patients with high-risk non-seminomatous germ cell tumor Oncology 78 2010 47 53
96. A. Lorch, A. Kleinhans, A. Kramar, and et al. Sequential versus single high-dose chemotherapy in patients with relapsed or refractory germ cell tumors: long-term results of a prospective randomized trial J Clin Oncol 30 2012 800 805
97. J. Oldenburg, J.M. Martin, and S.D. Fossa Late relapses of germ cell malignancies: incidence, management, and prognosis J Clin Oncol 24 2006 5503 5511
98. J. Beyer, P. Albers, R. Altena, and et al. Maintaining success, reducing treatment burden, focusing on survivorship: highlights from the third European consensus conference on diagnosis and treatment of germ-cell cancer Ann Oncol 24 2013 878 888
99. J. Baniel, R.S. Foster, R. Gonin, J.E. Messemer, J.P. Donohue, and L.H. Einhorn Late relapse of testicular cancer J Clin Oncol 13 1995 1170 1176
100. D.W. George, R.S. Foster, R.A. Hromas, and et al. Update on late relapse of germ cell tumor: a clinical and molecular analysis J Clin Oncol 21 2003 113 122
101. J. Oldenburg, G.C. Alfsen, H. Waehre, and S.D. Fossa Late recurrences of germ cell malignancies: a population-based experience over three decades Br J Cancer 94 2006 820 827
102. M.E. Lipphardt, and P. Albers Late relapse of testicular cancer World J Urol 22 2004 47 54
103. M.E. Gels, H.J. Hoekstra, D.T. Sleijfer, and et al. Detection of recurrence in patients with clinical stage I nonseminomatous testicular germ cell tumors and consequences for further follow-up: a single-center 10-year experience J Clin Oncol 13 1995 1188 1194